Rocket Pharmaceuticals Announces Participation At The BofA Securities 2020 Health Care Conference

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders, today announces that Gaurav Shah, M.
Author:
Publish date:

Rocket Pharmaceuticals, Inc. (RCKT) - Get Report ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket is scheduled to present on Wednesday, May 13, 2020, at 11:40 a.m. Eastern Time at the BofA Securities Virtual Health Care Conference

A live audio webcast of the presentation will be available on the Investors section of the company's website, www.rocketpharma.com. A replay of the presentation will be archived on the Rocket website following the conference.

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc. (RCKT) - Get Report ("Rocket") is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare disorders. The company's platform-agnostic approach enables it to design the best therapy for each indication, creating potentially transformative options for patients afflicted with rare genetic diseases. Rocket's clinical programs using lentiviral vector (LVV)-based gene therapy are for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD) a rare, monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. Rocket's first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon disease, a devastating, pediatric heart failure condition. Rocket's pre-clinical pipeline program is for Infantile Malignant Osteopetrosis (IMO), a bone marrow-derived disorder. For more information about Rocket, please visit www.rocketpharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200505005079/en/